FibroGen, Inc. (FGEN - Free Report) was a big mover last session, as the company saw its shares rise over 48% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $32.55 to $35.55 in the past one-month time frame.
The stock gained after issuing the positive results from its phase II trial testing of its idiopathic pulmonary fibrosis therapy.
The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter has moved lower over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
FibroGen currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
A better-ranked stock in the Medical - Drugs industry is Alpine Immune Sciences, Inc. (ALPN - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is FGEN going up? Or down? Predict to see what others think: Up or Down
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>